Drugs / allogeneic adoptive immune therapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02648516 | Oct 2016 → Jul 2021 | HIV infectious disease, immunodeficiency-related disorder | Beijing 302 Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | allogeneic adoptive immune therapy | “The purpose of this study is to investigate the safety and initial efficacy of allogeneic adoptive immune therapy (AAIT) for INR patients.” NCT02648516 ↗ |
| Known as | AAIT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02648516 ↗ |
| Action | Restore | “restore or boost the host holistic immune system” NCT02648516 ↗ |
| Modality | Cell therapy | “human leukocyte antigen (HLA)-mismatched MNCs transfusion can be used to comprehensively restore or boost the host holistic immune system for INR patients” NCT02648516 ↗ |
| Route | Intravenous | “20 INR patients received i.v. transfusion” NCT02648516 ↗ |